Drug intelligence / Profile preview

iRIV-XT

Development stage: Unknown
Lead developer: Rivchem Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

iRIV-XT is an oral nutritional supplement tablet developed by Rivchem Pharmaceuticals. It is a fixed-dose combination of ferrous ascorbate, folic acid, cyanocobalamin (vitamin B12), and zinc. The supplement is primarily indicated for the treatment and prevention of nutritional deficiencies and iron deficiency anemia, particularly in conditions such as pregnancy, menstruation, poor diet, or recovery after blood loss. Ferrous ascorbate provides a highly bioavailable form of iron to replenish iron stores and support hemoglobin synthesis, while folic acid and cyanocobalamin are essential for red blood cell production and DNA synthesis. Zinc is included to support immune function, cellular metabolism, and overall growth.

Brand names: iRIV-XT
Other names: Ferrous Ascorbate + Folic Acid + Cyanocobalamin + ZincIriv-XT

Beyond the preview

Go deeper on iRIV-XT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iRIV-XT.

Explore the full profile